Drug Combination Details
General Information of the Combination (ID: C89761) | |||||
---|---|---|---|---|---|
Name | Tetrandrine NP Info | + | Cisplatin Drug Info | ||
Structure |
![]() |
+ |
![]() |
||
Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CTNNB1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | WNT5A | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | WNT5B | Molecule Info |
Pathway MAP
|
||
In-vitro Model | OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo. |
![](/sites/default/files/kegg_pathway/hsa04210+581.png)
![](/sites/default/files/kegg_pathway/hsa04210+596.png)
![](/sites/default/files/kegg_pathway/hsa04210+836.png)
![](/sites/default/files/kegg_pathway/hsa04514+999.png)
![](/sites/default/files/kegg_pathway/hsa05200+1499.png)
![](/sites/default/files/kegg_pathway/hsa04210+142.png)
![](/sites/default/files/kegg_pathway/hsa04370+7422.png)
![](/sites/default/files/kegg_pathway/hsa04310+7474.png)
![](/sites/default/files/kegg_pathway/hsa04310+81029.png)